1/15
08:29 pm
artv
Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored [Seeking Alpha]
Medium
Report
Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored [Seeking Alpha]
1/8
03:30 am
artv
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
Low
Report
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
1/8
03:30 am
artv
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
Low
Report
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
12/19
06:30 pm
artv
Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO's Latest Insider Share Sale [Yahoo! Finance]
Medium
Report
Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO's Latest Insider Share Sale [Yahoo! Finance]
12/14
06:16 am
artv
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
High
Report
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
11/22
07:56 am
artv
Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
11/12
02:21 pm
artv
Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.
11/12
10:31 am
artv
Artiva Biotherapeutics GAAP EPS of -$0.88 [Seeking Alpha]
High
Report
Artiva Biotherapeutics GAAP EPS of -$0.88 [Seeking Alpha]
11/12
08:21 am
artv
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease [Yahoo! Finance]
Medium
Report
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease [Yahoo! Finance]
11/12
07:20 am
artv
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
High
Report
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
11/12
07:00 am
artv
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
High
Report
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/3
04:05 pm
artv
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
Medium
Report
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
10/30
06:27 pm
artv
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November [Yahoo! Finance]
Low
Report
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November [Yahoo! Finance]
10/30
04:17 pm
artv
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
Medium
Report
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
10/30
12:25 pm
artv
Artiva Biotherapeutics (NASDAQ:ARTV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.